CN108434382A - It is a kind of to be used to treat pharmaceutical composition of myocardial infarction and preparation method thereof - Google Patents
It is a kind of to be used to treat pharmaceutical composition of myocardial infarction and preparation method thereof Download PDFInfo
- Publication number
- CN108434382A CN108434382A CN201810520113.2A CN201810520113A CN108434382A CN 108434382 A CN108434382 A CN 108434382A CN 201810520113 A CN201810520113 A CN 201810520113A CN 108434382 A CN108434382 A CN 108434382A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- myocardial infarction
- safron
- jujube
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/24—Mucus; Mucous glands; Bursa; Synovial fluid; Arthral fluid; Excreta; Spinal fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9062—Alpinia, e.g. red ginger or galangal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of pharmaceutical compositions for treating myocardial infarction, it is made of the bulk pharmaceutical chemicals of following parts by weight：10 ~ 15 parts of Radix Salviae Miltiorrhizae, 2 ~ 3 parts of jujube, 1 ~ 5 part of safron, 3 ~ 6 parts of cortex albiziae, 1 ~ 3 part of galanga galangal seed, 2 ~ 5 parts of Poria cocos, 6 ~ 8 parts of the root bark of tree peony, 0.5 ~ 1 part of pueraria lobata, 2 ~ 5 parts of caulis sinomenii, 1 ~ 2 part of excrementum pteropi, 2 ~ 3 parts of black false hellebore, 1 ~ 2 part of raspberry, 2 ~ 3 parts of lophatherum gracile.The pharmaceutical composition can effectively reduce the blood viscosity of cardiovascular and cerebrovascular patient, have certain curative effect to treatment myocardial infarction.
Description
Technical field
The invention belongs to myocardial infarction drug therapy techniques fields, and in particular to a kind of drug for treating myocardial infarction
Composition and preparation method thereof.
Background technology
Normal human's blood vessel has complete endothelium, and endothelium is smooth, and unobstructed blood is without hindrance.But due to human body intake
Nutriment is different, is easy to form hypertension, hyperlipidemia, hyperglycemia etc., and lipid increases in blood, and platelet aggregation is attached to
On vascular wall, atherosclerotic plaque is slowly formed, patch, which becomes larger, so that lumen of vessels is narrowed, and influence supply of blood flow heart and big
Brain.The vessel endothelium and induced endothelial of blood vessel, blood vessel elasticity are deteriorated, and are easily broken to form thrombus blocking tube chamber.Cardiovascular disease is due to arterial blood
Inside pipe wall fat, cholesterol deposition, and it is accompanied by artery sclerosis.Coronary disease is then formed when this pathological development to heart coronary artery
Disease, including：Angina pectoris, myocardial infarction and acute death.Cerebrovascular disease be due to various reasons caused by the cerebrovascular block or
Rupture causes cerebrovascular function obstacle, causes related symptoms, is a kind of common frdquently encountered disease endangering life-threatening.In hemorrhagic brain
Bellows chamber includes two kinds of diseases of cerebral hemorrhage and subarachnoid hemorrhage；Ischemia apoplexy includes cerebral thrombus, cerebral embolism, lacunar brain
Four kinds of diseases such as infraction and transient ischemic attack.
Chinese traditional treatment myocardial infarction frequently with the same time using a variety of Chinese medicines to activate blood circulation and disperse blood clots, according to the difference of individual
It is different, it is dialectical to treat, vascular endothelial cell is repaired, lysed blood acid esters rubbish softens blood vessel, by improving microcirculation, adjusts machine
Body immunity enhances blood vessel endothelium antithrombus formation ability, improves blood viscosity, restores whole body qi-blood circulating, helps heart and brain blood
Pipe disease, arteriosclerosis patient health are long-lived.
Invention content
The technical problem to be solved by the present invention is to：A kind of pharmaceutical composition for treating myocardial infarction is provided.
The present invention goes back technical problems to be solved：The above-mentioned preparation for treating the pharmaceutical composition of myocardial infarction is provided
Method.
Technical solution：
In order to solve the above technical problems, the present invention adopts the following technical scheme that：
A kind of pharmaceutical composition for treating myocardial infarction, it is made of the bulk pharmaceutical chemicals of following parts by weight：
10 ~ 15 parts of Radix Salviae Miltiorrhizae, 2 ~ 3 parts of jujube, 1 ~ 5 part of safron, 3 ~ 6 parts of cortex albiziae, 1 ~ 3 part of galanga galangal seed, 2 ~ 5 parts of Poria cocos, the root bark of tree peony 6
~ 8 parts, 0.5 ~ 1 part of pueraria lobata, 2 ~ 5 parts of caulis sinomenii, 1 ~ 2 part of excrementum pteropi, 2 ~ 3 parts of black false hellebore, 1 ~ 2 part of raspberry, 2 ~ 3 parts of lophatherum gracile.
Preferably, it is made of the bulk pharmaceutical chemicals of following parts by weight：
12 parts of Radix Salviae Miltiorrhizae, 2 parts of jujube, 1 part of safron, 4 parts of cortex albiziae, 3 parts of galanga galangal seed, 3 parts of Poria cocos, 8 parts of the root bark of tree peony, 0.5 part of pueraria lobata,
2 parts of caulis sinomenii, 2 parts of excrementum pteropi, 3 parts of black false hellebore, 1 part of raspberry, 2 parts of lophatherum gracile.
Preferably, it is made of the bulk pharmaceutical chemicals of following parts by weight：
15 parts of Radix Salviae Miltiorrhizae, 3 parts of jujube, 5 parts of safron, 6 parts of cortex albiziae, 3 parts of galanga galangal seed, 5 parts of Poria cocos, 6 parts of the root bark of tree peony, 0.5 part of pueraria lobata,
2 parts of caulis sinomenii, 1 part of excrementum pteropi, 2 parts of black false hellebore, 2 parts of raspberry, 3 parts of lophatherum gracile.
Preferably, it is made of the bulk pharmaceutical chemicals of following parts by weight：
12 parts of Radix Salviae Miltiorrhizae, 2 parts of jujube, 4 parts of safron, 5 parts of cortex albiziae, 2 parts of galanga galangal seed, 4 parts of Poria cocos, 7 parts of the root bark of tree peony, 0.8 part of pueraria lobata,
3 parts of caulis sinomenii, 1.5 parts of excrementum pteropi, 2.8 parts of black false hellebore, 1.5 parts of raspberry, 2 parts of lophatherum gracile.
Wherein, dosage form made of described pharmaceutical composition is tablet, pill, powder, tincture, suspension, emulsion, solution
Agent, syrup, aerosol or capsule
The above-mentioned preparation method for treating the pharmaceutical composition of myocardial infarction includes the following steps：
(1) it weighs by weight respectively：10 ~ 15 parts of Radix Salviae Miltiorrhizae, 2 ~ 3 parts of jujube, 1 ~ 5 part of safron, 3 ~ 6 parts of cortex albiziae, galanga galangal seed
1 ~ 3 part, 2 ~ 5 parts of Poria cocos, 6 ~ 8 parts of the root bark of tree peony, 0.5 ~ 1 part of pueraria lobata, 2 ~ 5 parts of caulis sinomenii, 1 ~ 2 part of excrementum pteropi, 2 ~ 3 parts of black false hellebore covers basin
1 ~ 2 part of son, 2 ~ 3 parts of lophatherum gracile mix, grinding；
(2) ethanol solution of 6 ~ 10 times of volume of mixture is added in the mixture obtained to step (1), under the conditions of 40 ~ 50 DEG C
3 ~ 5h is handled, filtrate is collected in filtering, and then the ethyl alcohol in decompression removal filtrate, stands filtrate, upper layer grease is isolated
Come, had both obtained the pharmaceutical composition for treating myocardial infarction.
Advantageous effect：
The invention discloses a kind of pharmaceutical composition for treating myocardial infarction, which can effectively reduce heart and brain blood
The blood viscosity of pipe patient has certain curative effect to treatment myocardial infarction.
Specific implementation mode
According to following embodiments, the present invention may be better understood.However, as it will be easily appreciated by one skilled in the art that real
It applies content described in example and is merely to illustrate the present invention, without sheet described in detail in claims should will not be limited
Invention.
Embodiment 1：
Prescription：
12 parts of Radix Salviae Miltiorrhizae, 2 parts of jujube, 1 part of safron, 4 parts of cortex albiziae, 3 parts of galanga galangal seed, 3 parts of Poria cocos, 8 parts of the root bark of tree peony, 0.5 part of pueraria lobata,
2 parts of caulis sinomenii, 2 parts of excrementum pteropi, 3 parts of black false hellebore, 1 part of raspberry, 2 parts of lophatherum gracile.
Preparation process：
(1) it weighs by weight respectively：12 parts of Radix Salviae Miltiorrhizae, 2 parts of jujube, 1 part of safron, 4 parts of cortex albiziae, 3 parts of galanga galangal seed, Poria cocos 3
Part, 8 parts of the root bark of tree peony, 0.5 part of pueraria lobata, 2 parts of caulis sinomenii, 2 parts of excrementum pteropi, 3 parts of black false hellebore, 1 part of raspberry, 2 parts of lophatherum gracile, mixing are ground
Mill；
(2) in the mixture obtained to step (1) be added 10 times of volume of mixture ethanol solution, under the conditions of 40 ~ 50 DEG C at
3 ~ 5h is managed, filtrate is collected in filtering, and then the ethyl alcohol in decompression removal filtrate, stands filtrate, upper layer grease is separated,
Both the pharmaceutical composition for treating myocardial infarction had been obtained.
According to mass ratio it is 5 by obtained pharmaceutical composition and gelatin, maltodextrin, talcum powder:1:2:1 mixing, prepares
Obtain the tablet containing treatment myocardial infarction pharmaceutical composition.
Embodiment 2：
Prescription：
15 parts of Radix Salviae Miltiorrhizae, 3 parts of jujube, 5 parts of safron, 6 parts of cortex albiziae, 3 parts of galanga galangal seed, 5 parts of Poria cocos, 6 parts of the root bark of tree peony, 0.5 part of pueraria lobata,
2 parts of caulis sinomenii, 1 part of excrementum pteropi, 2 parts of black false hellebore, 2 parts of raspberry, 3 parts of lophatherum gracile.
Preparation process：
(1) it weighs by weight respectively：15 parts of Radix Salviae Miltiorrhizae, 3 parts of jujube, 5 parts of safron, 6 parts of cortex albiziae, 3 parts of galanga galangal seed, Poria cocos 5
Part, 6 parts of the root bark of tree peony, 0.5 part of pueraria lobata, 2 parts of caulis sinomenii, 1 part of excrementum pteropi, 2 parts of black false hellebore, 2 parts of raspberry, 3 parts of lophatherum gracile, mixing are ground
Mill；
(2) in the mixture obtained to step (1) be added 8 times of volume of mixture ethanol solution, under the conditions of 40 ~ 50 DEG C at
3 ~ 5h is managed, filtrate is collected in filtering, and then the ethyl alcohol in decompression removal filtrate, stands filtrate, upper layer grease is separated,
Both the pharmaceutical composition for treating myocardial infarction had been obtained.
According to mass ratio it is 5 by obtained pharmaceutical composition and gelatin, maltodextrin, talcum powder:1:2:1 mixing, prepares
Obtain the tablet containing treatment myocardial infarction pharmaceutical composition.
Embodiment 3：
Prescription：
12 parts of Radix Salviae Miltiorrhizae, 2 parts of jujube, 4 parts of safron, 5 parts of cortex albiziae, 2 parts of galanga galangal seed, 4 parts of Poria cocos, 7 parts of the root bark of tree peony, 0.8 part of pueraria lobata,
3 parts of caulis sinomenii, 1.5 parts of excrementum pteropi, 2.8 parts of black false hellebore, 1.5 parts of raspberry, 2 parts of lophatherum gracile.
Preparation process：
(1) it weighs by weight respectively：12 parts of Radix Salviae Miltiorrhizae, 2 parts of jujube, 4 parts of safron, 5 parts of cortex albiziae, 2 parts of galanga galangal seed, Poria cocos 4
Part, 7 parts of the root bark of tree peony, 0.8 part of pueraria lobata, 3 parts of caulis sinomenii, 1.5 parts of excrementum pteropi, 2.8 parts of black false hellebore, 1.5 parts of raspberry, 2 parts of lophatherum gracile mix
It closes, grinding；
(2) in the mixture obtained to step (1) be added 6 times of volume of mixture ethanol solution, under the conditions of 40 ~ 50 DEG C at
3 ~ 5h is managed, filtrate is collected in filtering, and then the ethyl alcohol in decompression removal filtrate, stands filtrate, upper layer grease is separated,
Both the pharmaceutical composition for treating myocardial infarction had been obtained.
According to mass ratio it is 5 by obtained pharmaceutical composition and gelatin, maltodextrin, talcum powder:1:2:1 mixing, prepares
Obtain the tablet containing treatment myocardial infarction pharmaceutical composition.
Embodiment 4：
Prescription：
13 parts of Radix Salviae Miltiorrhizae, 3 parts of jujube, 2 parts of safron, 3 parts of cortex albiziae, 1 part of galanga galangal seed, 3 parts of Poria cocos, 7 parts of the root bark of tree peony, 0.8 part of pueraria lobata,
3 parts of caulis sinomenii, 1 part of excrementum pteropi, 3 parts of black false hellebore, 2 parts of raspberry, 2 parts of lophatherum gracile.
Preparation process：
(1) it weighs by weight respectively：13 parts of Radix Salviae Miltiorrhizae, 3 parts of jujube, 2 parts of safron, 3 parts of cortex albiziae, 1 part of galanga galangal seed, Poria cocos 3
Part, 7 parts of the root bark of tree peony, 0.8 part of pueraria lobata, 3 parts of caulis sinomenii, 1 part of excrementum pteropi, 3 parts of black false hellebore, 2 parts of raspberry, 2 parts of lophatherum gracile, mixing are ground
Mill；
(2) ethanol solution of 6 ~ 10 times of volume of mixture is added in the mixture obtained to step (1), under the conditions of 40 ~ 50 DEG C
3 ~ 5h is handled, filtrate is collected in filtering, and then the ethyl alcohol in decompression removal filtrate, stands filtrate, upper layer grease is isolated
Come, had both obtained the pharmaceutical composition for treating myocardial infarction.
According to mass ratio it is 5 by obtained pharmaceutical composition and gelatin, maltodextrin, talcum powder:1:2:1 mixing, prepares
Obtain the tablet containing treatment myocardial infarction pharmaceutical composition.
Embodiment 5：Influence of the pharmaceutical composition to myocardial infarction.
Rat every group 10（Half male and half female, 200 ~ 250g/ of weight is only）.It is fixed with anesthesia, trachea cannula, on the left of breastbone
Ancestor's notch of 1.5cm is done, the 3rd, 4 cartilage is cut in nearly breastbone side, after opening thoracic cavity, connects lung ventilator, cuts off pericardium, exposure
Heart, coronary artery left anterior descending branch root threading stablize 15min in case ligation, records electrocardiogram, and following coronary artery occlusion is left front
Descending branch closes thoracic cavity.The secretion of rat throat is sucked out with syringe, rat restores breathing.After following coronary artery occlusion 15min, tail vein
Administration.After following coronary artery occlusion 3 hours, heart is won, crosscutting 5 below ligature, carries out the dyeing of chlorination nitro tetrazole,
Calculating myocardium Infarct area accounts for the percentage of ventricle and heart area, carries out statistical procedures, and experimental result is as follows：
Influence of 1 pharmaceutical composition of table to myocardial infarction
From experimental result as can be seen that the obtained pharmaceutical composition of the present invention to the myocardial infarction caused by myocardial infarction have compared with
Good therapeutic effect, moreover, the infarct size of heart and ventricle can be substantially reduced by increasing dosage.
Claims (7)
1. a kind of pharmaceutical composition for treating myocardial infarction, which is characterized in that it is by the bulk pharmaceutical chemicals system of following parts by weight
At：
10 ~ 15 parts of Radix Salviae Miltiorrhizae, 2 ~ 3 parts of jujube, 1 ~ 5 part of safron, 3 ~ 6 parts of cortex albiziae, 1 ~ 3 part of galanga galangal seed, 2 ~ 5 parts of Poria cocos, the root bark of tree peony 6
~ 8 parts, 0.5 ~ 1 part of pueraria lobata, 2 ~ 5 parts of caulis sinomenii, 1 ~ 2 part of excrementum pteropi, 2 ~ 3 parts of black false hellebore, 1 ~ 2 part of raspberry, 2 ~ 3 parts of lophatherum gracile.
2. the pharmaceutical composition according to claim 1 for treating myocardial infarction, which is characterized in that it is by weighing as follows
The bulk pharmaceutical chemicals of amount part are made：
12 parts of Radix Salviae Miltiorrhizae, 2 parts of jujube, 1 part of safron, 4 parts of cortex albiziae, 3 parts of galanga galangal seed, 3 parts of Poria cocos, 8 parts of the root bark of tree peony, 0.5 part of pueraria lobata,
2 parts of caulis sinomenii, 2 parts of excrementum pteropi, 3 parts of black false hellebore, 1 part of raspberry, 2 parts of lophatherum gracile.
3. the pharmaceutical composition according to claim 1 for treating myocardial infarction, which is characterized in that it is by weighing as follows
The bulk pharmaceutical chemicals of amount part are made：
15 parts of Radix Salviae Miltiorrhizae, 3 parts of jujube, 5 parts of safron, 6 parts of cortex albiziae, 3 parts of galanga galangal seed, 5 parts of Poria cocos, 6 parts of the root bark of tree peony, 0.5 part of pueraria lobata,
2 parts of caulis sinomenii, 1 part of excrementum pteropi, 2 parts of black false hellebore, 2 parts of raspberry, 3 parts of lophatherum gracile.
4. the pharmaceutical composition according to claim 1 for treating myocardial infarction, which is characterized in that it is by weighing as follows
The bulk pharmaceutical chemicals of amount part are made：
12 parts of Radix Salviae Miltiorrhizae, 2 parts of jujube, 4 parts of safron, 5 parts of cortex albiziae, 2 parts of galanga galangal seed, 4 parts of Poria cocos, 7 parts of the root bark of tree peony, 0.8 part of pueraria lobata,
3 parts of caulis sinomenii, 1.5 parts of excrementum pteropi, 2.8 parts of black false hellebore, 1.5 parts of raspberry, 2 parts of lophatherum gracile.
5. according to any pharmaceutical composition for treating myocardial infarction of claim 1 ~ 4, which is characterized in that
Dosage form made of described pharmaceutical composition is tablet, pill, powder, tincture, suspension, emulsion, solution, syrup, aerosol
Agent or capsule.
6. power requires the preparation method of the pharmaceutical composition for treating myocardial infarction described in 1, which is characterized in that including as follows
Step：
(1) it weighs by weight respectively：10 ~ 15 parts of Radix Salviae Miltiorrhizae, 2 ~ 3 parts of jujube, 1 ~ 5 part of safron, 3 ~ 6 parts of cortex albiziae, galanga galangal seed
1 ~ 3 part, 2 ~ 5 parts of Poria cocos, 6 ~ 8 parts of the root bark of tree peony, 0.5 ~ 1 part of pueraria lobata, 2 ~ 5 parts of caulis sinomenii, 1 ~ 2 part of excrementum pteropi, 2 ~ 3 parts of black false hellebore covers basin
1 ~ 2 part of son, 2 ~ 3 parts of lophatherum gracile mix, grinding；
(2) ethanol solution of 6 ~ 10 times of volume of mixture is added in the mixture obtained to step (1), under the conditions of 40 ~ 50 DEG C
3 ~ 5h is handled, filtrate is collected in filtering, and then the ethyl alcohol in decompression removal filtrate, stands filtrate, upper layer grease is isolated
Come, had both obtained the pharmaceutical composition for treating myocardial infarction.
7. the preparation method according to claim 6 for treating the pharmaceutical composition of myocardial infarction, which is characterized in that step
Suddenly（2）In, the volume fraction of ethyl alcohol is 70% in the ethanol solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810520113.2A CN108434382A (en) | 2018-05-28 | 2018-05-28 | It is a kind of to be used to treat pharmaceutical composition of myocardial infarction and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810520113.2A CN108434382A (en) | 2018-05-28 | 2018-05-28 | It is a kind of to be used to treat pharmaceutical composition of myocardial infarction and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108434382A true CN108434382A (en) | 2018-08-24 |
Family
ID=63205655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810520113.2A Pending CN108434382A (en) | 2018-05-28 | 2018-05-28 | It is a kind of to be used to treat pharmaceutical composition of myocardial infarction and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108434382A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113368081A (en) * | 2021-05-24 | 2021-09-10 | 杭州仁德医药有限公司 | A Chinese medicinal patch for treating cerebral thrombosis, and its preparation method |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1176820A (en) * | 1997-09-26 | 1998-03-25 | 操瑞明 | Red ginseng and hawthorn fruit health-care wine |
| CN105596922A (en) * | 2014-03-07 | 2016-05-25 | 陈西成 | Blood circulation invigorating and vein relaxing powder for treating coronary heart disease |
-
2018
- 2018-05-28 CN CN201810520113.2A patent/CN108434382A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1176820A (en) * | 1997-09-26 | 1998-03-25 | 操瑞明 | Red ginseng and hawthorn fruit health-care wine |
| CN105596922A (en) * | 2014-03-07 | 2016-05-25 | 陈西成 | Blood circulation invigorating and vein relaxing powder for treating coronary heart disease |
Non-Patent Citations (1)
| Title |
|---|
| 王晶等: "自拟方治疗胸痹50例疗效观察", 《中医函授通讯》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113368081A (en) * | 2021-05-24 | 2021-09-10 | 杭州仁德医药有限公司 | A Chinese medicinal patch for treating cerebral thrombosis, and its preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103919854B (en) | Application of butterflybush flower and extract thereof to preparation of medicament | |
| CN103006838A (en) | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases | |
| CN108403882B (en) | Salvia miltiorrhiza composition for treating coronary heart disease and preparation method thereof | |
| CN108434382A (en) | It is a kind of to be used to treat pharmaceutical composition of myocardial infarction and preparation method thereof | |
| CN103006769A (en) | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN101632726B (en) | Application of Chinese medicinal composition in preparing medicament for treating blood vessel micro-embolization | |
| CN101590180A (en) | The application of a kind of Chinese medicine composition in preparation inhibition apoptosis of cardiac muscle medicine | |
| CN101653488B (en) | Application of Chinese medicinal composition in preparation of medicament for resisting myocardial stunning | |
| CN102204956B (en) | Chinese medicinal composition used at stroke recovery period and preparation method thereof | |
| CN101112405B (en) | Drug for curing coronary disease and method for preparing the same | |
| CN100496481C (en) | Medicinal composition for treating cardio-cerebral-vascular disease and its preparing method | |
| CN1582946B (en) | Use of centellosic acid derivative in preparation of medicines for diseases of cardio-cerebral blood vessels | |
| CN110548099A (en) | Traditional Chinese medicine composition for treating coronary heart disease stable angina pectoris and preparation method thereof | |
| CN105535890B (en) | A kind of pharmaceutical composition and preparation method thereof for treating cardiovascular disease | |
| CN101161268B (en) | Pharmaceutical composition of red sage root and cattail pollen | |
| CN109568481A (en) | A kind of Chinese prescription preparation for treating coronary heart disease | |
| CN100384439C (en) | Medicinal composition for treating and/or preventing heart brnin blood vessel disease and its preparation method | |
| CN102988478A (en) | Traditional Chinese medicine combination for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN101856403B (en) | Medicinal composition, preparation method thereof and pharmaceutical application | |
| CN100482235C (en) | 2-glucoside Chinese medicinal oral preparation and its making method thereof | |
| CN102370735B (en) | Application of traditional Chinese medicinal composition in preparation of medicament for treating polycythemia | |
| CN101390973A (en) | Use of traditional Chinese medicine in preparing medicine for treating retinal vein obstruction | |
| CN101190253B (en) | Medicinal composition containing mongolian snakegourd and notoginseng | |
| CN101152246A (en) | Pharmaceutical composition for cardiovascular and cerebrovascular diseases and method for preparing the same | |
| CN102961445A (en) | Medicinal composition for assisting to reduce blood fat and blood pressure and capsule preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180824 |